Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Access to the ClinicalTrials.gov study record for NCT03950674 now returns a 403 Forbidden page instead of the study details. The screen shows a 403 message and a Home button, signaling the record is temporarily inaccessible due to permissions.
    Difference
    22%
    Check dated 2026-09-20T04:32:31.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The page content remains unchanged; there are no new edits or additions to interpret in context.
    Difference
    0.0%
    Check dated 2026-09-13T01:56:35.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The page's revision tag was updated to v3.6.6, signaling a minor maintenance update to the record. No substantive information about the study is changed.
    Difference
    0.0%
    Check dated 2026-08-29T23:41:15.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    A new revision tag 'Revision: v3.6.5' has been added, replacing 'Revision: v3.6.4'. This indicates an updated revision history for the page.
    Difference
    0.0%
    Check dated 2026-08-08T19:52:19.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Revision: v3.6.4 replaces the previous Revision: v3.6.3, indicating a recent update to the page’s content or functionality.
    Difference
    0.0%
    Check dated 2026-07-25T12:36:16.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    Added Revision: v3.6.3 and removed Revision: v3.6.2, signaling a new page release. This appears to be a minor metadata/update rather than content changes to the study details.
    Difference
    0.0%
    Check dated 2026-07-03T23:59:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.